Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097189 | 0.91 | PTGS2 (0.51) | PTGS2PTGS1PDPK1EPHX2CYP2C9 | |
| SCHEMBL4246189 | 0.80 | PTGS2 (0.56) | PTGS2PTGS1EPHX2CYP2C9MAPT | |
| SCHEMBL6097255 | 0.80 | CA1 (0.46) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6097217 | 0.77 | PTGS1 (0.55) | PTGS2PTGS1PDPK1CYP2C9MAPT | |
| SCHEMBL4252961 | 0.75 | PTAFR (0.54) | PTGS2EPHX2CYP2C9MAPT | |
| SCHEMBL4246867 | 0.74 | EPHX2 (0.64) | PTGS2PTGS1EPHX2CYP2C9MAPT | |
| SCHEMBL4248311 | 0.73 | EPHX2 (0.61) | PTGS2PTGS1EPHX2CYP2C9MAPT | |
| SCHEMBL6097735 | 0.72 | PTGS1 (0.70) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6097074 | 0.72 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL6098312 | 0.72 | CA1 (0.43) | PTGS2EPHX2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | PTGS2 10/4885PTGS1 2/4885PDPK1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.